- 爭取疫苗代工變數多 專家建議籌組國家隊 - 自由財經自由時報電子報2021年06月12日 15:28
- 取消第三期試驗？中國疫苗定位惹議 網友炸鍋(圖) - - 大陸時政看中國2021年06月09日 00:38
- 蒙古接種者過半疫情反升 中國國藥疫苗再受質疑大紀元2021年06月11日 14:15
- 焦點評論》誰會打擊疫苗自主自由時報電子報2021年06月12日 05:30
- 萌蒂制藥中國業務競標火熱！博裕資本、國藥集團參與其中_財經_中國網日前，據路透社援引兩位知情人士稱，萌蒂制藥（Mundipharma）已將博裕資本（Boyu Capital）和中國國藥集團（Sinopharm）列入其在華業務的競標者名單。中國網2021年06月11日 03:00
China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the +Learn more HEALTH SERVICES
10/5/2021 · The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued Interim recommendations for the use of the inactivated COVID-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group. Here is what you need to know.
查看最新的 SINOPHARM (1099.HK) 股票報價、記錄、新聞及其他重要資訊，助你賣買股票及投資。
Sinopharm Group. Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and ...
27/5/2021 · Study: Sinopharm COVID-19 vaccines appear safe, effective Two vaccines made by China’s Sinopharm appear to be safe and effective against COVID-19, according to a study published in a medical journal
Who is the parent company of Sinopharm pharmaceutical?
What does the Sinopharm Group do for a living?
Who is Sinopharm and what is Guoda pharmacy?
When did Sinopharm Group IPO in Hong Kong?
- What Is The Sinopharm Vaccine?
- Is It More Effective That The Other ones?
- Where Is It Being used?
- How Many Doses Are Being Made?
Sinopharm Group is a state-owned pharmaceutical company with two vaccine candidates among China’s five experimental treatment in international final stage trials. The vaccines are not being trialled in China because the domestic prevalence of the virus is so low. Sinopharm’s vaccine and bioscience subsidiary is the ChinaNational Biotec Group Co Ltd (CNBG). Public statements about Sinopharm vaccines do not appear to clarify which of the two candidates are being discussed. Sinopharm is among two Chinese pharmaceutical companies (the other is fellow frontrunner Sinovac) to have created their vaccine via the more traditional method of using an inactive virus to trigger an immune response. They are more difficult to manufacture quickly than the others, and have the potential to cause an imbalanced immune response, but have shown historic success.
Pfizer/BioNTech and Moderna have both reported 95% efficacy with their vaccines, while AstraZeneca’s 70% efficacy in full trials rose to 90%for the group who were given a half dose of the vaccine initially, followed by a full dose four weeks later. This week the United Arab Emirates said clinical trials of Sinopharm’s vaccine – including 31,000 volunteers across 125 nationalities in the federation of sheikdoms – found 86% efficacy. Last month Sinopharm announced that about 1 million people had been given emergency doses, and “only individual patients have had some mild symptoms”, but the lack of transparency has prompted some concern among health experts. Professor Terry Nolan, head of the Peter Doherty Institute’s vaccine and immunisation research group, told the Guardian the statement, taken at face value, was “a pretty good early indication about the safety of one of the vaccine types”. “And frankly it’s the type which would be more likely to have adverse effects,” he said referr...
A Sinopharm vaccine has been approved for emergency use in a few countries and the company has been conducting late-stage clinical trials in 10 nations including Argentina, the UAE and Morocco. It has also been trialled in Peru but the country suspended tests due to a “serious adverse event” that occurred with one of the volunteers for the study, the Peruvian government said on Saturday. In September, the UAE was the first country outside China to approve emergency use of a Sinopharm vaccine. Jamal Al Kaabi, a senior UAE health official told CNN this week almost 100,000 volunteers had received the vaccine so far. In Bahrain the vaccine is now available to frontline healthcare workers after 7,700 people participated in clinical trials, and Egypt received its first shipment of a Chinese coronavirus vaccine on Thursday. Morocco is also planning to rely on the Sinopharm jab to meet its ambitious aim to vaccinate 80% of its adults. China has made potentially conflicting promises to a num...
Specific information on doses is not available. Some media reports have said Sinopharm’s subsidiary could supply 100m doses this year, potentially expanding capacity to produce 300m. Last week health authorities said China would have 600m doses ready for market by the end of this year. At a briefing in Wuhan, Wang Junzhi, deputy head of an expert task force on vaccine development, did not say which company’s vaccines would be rolled out but described them as “inactive” vaccines, narrowing it down to those being developed by Sinopharm and Sinovac. Additional reporting by AP
27/5/2021 · The Chinese drug maker Sinopharm has finally published the interim results from a phase 3 trial of its Covid-19 vaccine after more than 200 million doses have been administered worldwide.
- A Vaccine Made from Coronaviruses
- Killing The Virus
- Prompting An Immune Response
- Making Antibodies
- Stopping The Virus
- Remembering The Virus
- Vaccine Timeline
BBIBP-CorV works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface. To create BBIBP-CorV, the Beijing Institute researchers obtained three variants of the coronavirus from patients in Chinese hospitals. They picked one of the variants because it was able to multiply quickly in monkey kidney cells grown in bioreactor tanks.
Once the researchers produced large stocks of the coronaviruses, they doused them with a chemical called beta-propiolactone. The compound disabled the coronaviruses by bonding to their genes. The inactivated coronaviruses could no longer replicate. But their proteins, including spike, remained intact. The researchers then drew off the inactivated viruses and mixed them with a tiny amount of an aluminum-based compound called an adjuvant. Adjuvants stimulate the immune system to boost its response to a vaccine. Inactivated viruses have been used for over a century. Jonas Salk used them to create his polio vaccine in the 1950s, and they’re the bases for vaccines against other diseases including rabies and hepatitis A.
Because the coronaviruses in BBIBP-CorV are dead, they can be injected into the arm without causing Covid-19. Once inside the body, some of the inactivated viruses are swallowed up by a type of immune cell called an antigen-presenting cell. The antigen-presenting cell tears the coronavirus apart and displays some of its fragments on its surface. A so-called helper T cell may detect the fragment. If the fragment fits into one of its surface proteins, the T cell becomes activated and can help recruit other immune cells to respond to the vaccine.
Another type of immune cell, called a B cell, may also encounter the inactivated coronavirus. B cells have surface proteins in a huge variety of shapes, and a few might have the right shape to latch onto the coronavirus. When a B cell locks on, it can pull part or all of the virus inside and present coronavirus fragments on its surface. A helper T cell activated against the coronavirus can latch onto the same fragment. When that happens, the B cell gets activated, too. It proliferates and pours out antibodies that have the same shape as their surface proteins.
Once vaccinated with BBIBP-CorV, the immune system can respond to an infection of live coronaviruses. B cells produce antibodies that stick to the invaders. Antibodies that target the spike protein can prevent the virus from entering cells. Other kinds of antibodies may block the virus by other means.
Sinopharm’s clinical trials have demonstrated that BBIBP-CorV can protect people against Covid-19. But no one can yet say how long that protection lasts. It’s possible that the level of antibodies drops over the course of months. But the immune system also contains special cells called memory B cells that might retain information about the coronavirus for years or even decades.
January, 2020Sinopharm begins developing an inactivated vaccine against the coronavirus. June Researchers report the vaccine produces promising results in monkeys. A Phase 1/2 trialshows that the vaccine doesn’t cause any serious side effects and enables people to make antibodies against the coronavirus. July A Phase 3 trialbegins in the United Arab Emirates. August Phase 3 trials begin in Morocco and Peru. Sept. 14 The U.A.E. gives emergency approval for Sinopharm’s vaccine to use on health care workers. Government officialsand others begin to receive it. November The chairman of Sinopharm says almost a million peoplein China have received Sinopharm vaccines. Nov. 3 The ruler of Dubai, Sheikh Mohammed bin Rashid al-Maktoum, announceshe received the vaccine. Dec. 9 The U.A.E. gives full approval to BBIBP-CorV, announcing it has an efficacy rate of 86 percent. But the government did not release any details with their announcement, leaving it unclear how they had come to their conclus...
8/6/2021 · Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. Drugmaker Mundipharma has ...
29/5/2021 · Sinopharm is Thailand’s hot new vaccine, having been approved by the Food and Drug Administration yesterday, so what information do we have about the Covid-19 vaccine? The vaccine has been approved by World Health Organisation for people above ...